查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2141869

GLP-1/CGM融合市場洞察、競爭格局及市場預測 - 2033年

GLP-1 and CGM Convergence Market Insights, Competitive Landscape, and Market Forecast - 2033
出版日期: | 出版商: Fairfield Market Research | 英文 269 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

預計到 2033 年，GLP-1/CGM 融合市場將達到 36.5917 億美元。

介紹

全球GLP-1/CGM融合市場預計在2026年達到6.5億美元，並將在2026年至2033年間以28%的複合年成長率成長，到2033年達到36.5917億美元。 Fairfield Market Research透過其發布的市場區隔報告（包括產品、客戶和區域細分）對市場進行評估。該預測為評估整個研究期間的商業優先事項提供了一個通用標準。

市場洞察

產品類型包括GLP-1/CGM整合數位平台、具備GLP-1資料整合功能的獨立式CGM設備等。最終用戶包括第2型糖尿病患者、體重管理患者（非糖尿病）等。分銷管道包括直接面對消費者的銷售/遠端醫療和醫療服務提供者的處方。這些細分有助於企業評估哪些產品和客戶需求在其市場範圍內。全球預測應結合這些細分定義進行解讀，而不是簡單地應用於單一類別。

在產品類型分類中，本報告將整合GLP-1/CGM的數位平台和具有GLP-1資料整合功能的獨立CGM設備作為兩個獨立的類別進行分類。清楚區分這些類別有助於讀者在將整體市場預測應用於自身特定產業計畫之前，更輕鬆地評估其產品的適用性。

在最終用戶分類方面，本報告將第2型糖尿病患者和體重管理患者（非糖尿病患者）視為不同的類別。明確區分這些類別有助於讀者在將整體市場預測應用於特定產業計畫之前，更輕鬆地評估其產品和服務是否適合目標使用者。

本報告在對分銷管道進行分類時，將「直接面對消費者/遠端醫療」和「臨床/醫療服務提供者處方」視為兩個獨立的類別。明確區分這些類別將有助於讀者在將整體市場預測應用於具體產業計畫之前，評估其服務的適用性。

促進因素

Fairfield 的成長分析涵蓋了其 GLP-1 和 CGM 整合數位平台、2 型糖尿病患者以及直接面對消費者/遠端醫療。這些主題是評估市場需求格局和供應商所面臨要求的起點。它們的商業性重要性因目標細分市場、客戶和地區而異。企業可以利用本報告中的詳細洞察，將這些需求促進因素與其產品組合和銷售重點連結起來。

商業機會

我們對商業機會的分析著重於產品類型、最終用戶和分銷管道。考慮業務擴張的公司可以將這些方面與自身現有能力、市場進入管道和客戶需求進行比較。細分市場選擇和區域定位在評估已發布預測對各公司的相關性方面仍然至關重要。

考慮實施 GLP-1/CGM 整合數位平台的公司可以將自身客戶需求與具備 GLP-1 資料整合功能的獨立 CGM 設備的需求進行比較。這種比較有助於明確產品系列的重點，確定目標受眾，並在分配資源前明確哪些方面需要額外的細分資料。

針對第2型糖尿病患者的公司可以將他們的客戶需求與尋求體重管理的患者（非糖尿病患者）的需求進行比較。這種比較有助於制定更精準的產品組合，確定合適的目標受眾，並找出在投入資源之前需要更多細分數據支援的挑戰。

區域分析

Fairfield的區域分析指出，北美是主要市場。地理範圍涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。在進行區域間比較時，請使用本報告中特有的市場定義和預測期。

目錄

第1章摘要整理

第2章 市場概覽

  • 市場定義與細分
  • 市場動態
    • 促進因素
    • 抑制因子
    • 市場機遇
  • 價值鏈分析
  • 新冠疫情影響分析
  • 波特五力分析
  • 俄烏衝突的影響
  • PESTLE分析
  • 監管分析
  • 價格趨勢分析
    • 目前價格及未來預測（2025-2033年）
    • 影響價格的因素

第3章：2020-2033年全球GLP-1/CGM融合市場展望

  • 依產品類型
    • 整合式 GLP-1/CGM 數位平台
    • 具備GLP-1資料整合功能的獨立式CGM設備
    • 其他
  • 最終用戶
    • 2型糖尿病患者
    • 體重管理患者（非糖尿病患者）
    • 其他
  • 透過分銷管道
    • 直接面對消費者銷售/遠端醫療
    • 臨床/醫療服務提供者開立的處方
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第4章：2020-2033年北美GLP-1/CGM融合市場展望

  • 依產品類型
    • 整合式 GLP-1/CGM 數位平台
    • 具備GLP-1資料整合功能的獨立式CGM設備
    • 其他
  • 最終用戶
    • 2型糖尿病患者
    • 體重管理患者（非糖尿病患者）
    • 其他
  • 透過分銷管道
    • 直接面對消費者銷售/遠端醫療
    • 臨床/醫療服務提供者開立的處方
  • 國家
    • 美國
    • 加拿大
  • BPS分析與市場吸引力分析

第5章：2020-2033年歐洲GLP-1/CGM融合市場展望

  • 依產品類型
    • 整合式 GLP-1/CGM 數位平台
    • 具備GLP-1資料整合功能的獨立式CGM設備
    • 其他
  • 最終用戶
    • 2型糖尿病患者
    • 體重管理患者（非糖尿病患者）
    • 其他
  • 透過分銷管道
    • 直接面對消費者銷售/遠端醫療
    • 臨床/醫療服務提供者開立的處方
  • 國家
    • 德國
    • 義大利
    • 法國
    • 英國
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • BPS分析與市場吸引力分析

第6章：亞太地區GLP-1/CGM融合市場展望（2020-2033年）

  • 依產品類型
    • 整合式 GLP-1/CGM 數位平台
    • 具備GLP-1資料整合功能的獨立式CGM設備
    • 其他
  • 最終用戶
    • 2型糖尿病患者
    • 體重管理患者（非糖尿病患者）
    • 其他
  • 透過分銷管道
    • 直接面對消費者銷售/遠端醫療
    • 臨床/醫療服務提供者開立的處方
  • 國家
    • 中國
    • 日本
    • 韓國
    • 印度
    • 東南亞
    • 其他南亞、東協和大洋洲
  • BPS分析與市場吸引力分析

第7章：2020-2033年拉丁美洲GLP-1/CGM融合市場展望

  • 依產品類型
    • 整合式 GLP-1/CGM 數位平台
    • 具備GLP-1資料整合功能的獨立式CGM設備
    • 其他
  • 最終用戶
    • 2型糖尿病患者
    • 體重管理患者（非糖尿病患者）
    • 其他
  • 透過分銷管道
    • 直接面對消費者銷售/遠端醫療
    • 臨床/醫療服務提供者開立的處方
  • 國家
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲
  • BPS分析與市場吸引力分析

第8章：2020-2033年中東和非洲GLP-1和CGM融合市場展望

  • 依產品類型
    • 整合式 GLP-1/CGM 數位平台
    • 具備GLP-1資料整合功能的獨立式CGM設備
    • 其他
  • 最終用戶
    • 2型糖尿病患者
    • 體重管理患者（非糖尿病患者）
    • 其他
  • 透過分銷管道
    • 直接面對消費者銷售/遠端醫療
    • 臨床/醫療服務提供者開立的處方
  • 國家
    • GCC
    • 南非
    • 埃及
    • 奈及利亞
    • 其他中東和非洲地區
  • BPS分析與市場吸引力分析

第9章 競爭情勢

  • 按公司和細分市場分類的熱力圖
  • 企業市佔率分析，2025 年
  • 競爭對手儀表板
  • 公司簡介
    • Dexcom, Inc.
    • Abbott Laboratories
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Medtronic plc
    • Senseonics Holdings, Inc.
    • Roche Holding AG
    • Tandem Diabetes Care, Inc.
    • Insulet Corporation
    • Signos, Inc.

第10章附錄

簡介目錄

GLP-1 and CGM Convergence Market Projected to Reach US$3,659.17 Mn by 2033

Introduction

The global glp-1 and cgm convergence market is valued at US$650 Mn in 2026 and projected to reach US$3,659.17 Mn by 2033, at a CAGR of 28% during 2026-2033. Fairfield Market Research assesses the market through its published product, customer and geographical classifications. The forecast provides a common basis for evaluating commercial priorities across the study period.

Market Insights

The product type breakdown covers Integrated GLP-1/CGM Digital Platforms, Standalone CGM Devices with GLP-1 Data Integration and Others. The end user breakdown covers Individuals with Type 2 Diabetes, Weight Management Patients (Non-Diabetic) and Others. The distribution channel breakdown covers Direct-to-Consumer/Telehealth and Clinical/Provider-Prescribed. These distinctions help businesses assess which offerings and customer requirements fall within the market's scope. The global forecast should be read alongside these segment definitions rather than applied uniformly to every individual category.

Within the product type classification, Integrated GLP-1/CGM Digital Platforms and Standalone CGM Devices with GLP-1 Data Integration represent separate categories in the report. Keeping these categories distinct helps readers evaluate the fit of an offering before applying the overall market forecast to a specific commercial plan.

Within the end user classification, Individuals with Type 2 Diabetes and Weight Management Patients (Non-Diabetic) represent separate categories in the report. Keeping these categories distinct helps readers evaluate the fit of an offering before applying the overall market forecast to a specific commercial plan.

Within the distribution channel classification, Direct-to-Consumer/Telehealth and Clinical/Provider-Prescribed represent separate categories in the report. Keeping these categories distinct helps readers evaluate the fit of an offering before applying the overall market forecast to a specific commercial plan.

Drivers

Fairfield's growth discussion addresses integrated glp-1/cgm digital platforms, individuals with type 2 diabetes and direct-to-consumer/telehealth. These themes provide a starting point for assessing demand conditions and the requirements facing suppliers. Their commercial importance depends on the segment, customer and region concerned. Businesses can use the report's detailed discussion to connect these demand factors with their own portfolios and sales priorities.

Business Opportunity

The opportunity discussion highlights product type, end user and distribution channel. Companies evaluating expansion can compare these areas with their existing capabilities, route to market and customer needs. Segment selection and regional positioning remain central to assessing the relevance of the published forecast to an individual business.

Businesses considering Integrated GLP-1/CGM Digital Platforms can compare its customer requirements with those associated with Standalone CGM Devices with GLP-1 Data Integration. This comparison can help define a more focused portfolio, identify the appropriate sales audience and establish which questions require additional segment evidence before resources are committed.

Businesses considering Individuals with Type 2 Diabetes can compare its customer requirements with those associated with Weight Management Patients (Non-Diabetic). This comparison can help define a more focused portfolio, identify the appropriate sales audience and establish which questions require additional segment evidence before resources are committed.

Region Analysis

North America is identified in Fairfield's regional analysis as a leading market. The geographical scope covers North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Regional comparisons should use the report's own market definitions and forecast period.

Key Players

  • Dexcom, Inc.
  • Abbott Laboratories
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Medtronic plc
  • Senseonics Holdings, Inc.
  • Roche Holding AG
  • Tandem Diabetes Care, Inc.
  • Insulet Corporation
  • Signos, Inc.

Segmentation

By Product Type

  • Integrated GLP-1/CGM Digital Platforms
  • Standalone CGM Devices with GLP-1 Data Integration
  • Others

By End User

  • Individuals with Type 2 Diabetes
  • Weight Management Patients (Non-Diabetic)
  • Others

By Distribution Channel

  • Direct-to-Consumer/Telehealth
  • Clinical/Provider-Prescribed

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global GLP-1 and CGM Convergence Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 3.1. Global GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 3.1.1. Integrated GLP-1/CGM Digital Platforms
    • 3.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 3.1.3. Others
  • 3.2. Global GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 3.2.1. Individuals with Type 2 Diabetes
    • 3.2.2. Weight Management Patients (Non-Diabetic)
    • 3.2.3. Others
  • 3.3. Global GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 3.3.1. Direct-to-Consumer/Telehealth
    • 3.3.2. Clinical/Provider-Prescribed
  • 3.4. Global GLP-1 and CGM Convergence Market Outlook, by Region, Value (US$ Mn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 4.1. North America GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 4.1.1. Integrated GLP-1/CGM Digital Platforms
    • 4.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 4.1.3. Others
  • 4.2. North America GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 4.2.1. Individuals with Type 2 Diabetes
    • 4.2.2. Weight Management Patients (Non-Diabetic)
    • 4.2.3. Others
  • 4.3. North America GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 4.3.1. Direct-to-Consumer/Telehealth
    • 4.3.2. Clinical/Provider-Prescribed
  • 4.4. North America GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 4.4.1. U.S. GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 4.4.2. U.S. GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 4.4.3. U.S. GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 4.4.4. Canada GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 4.4.5. Canada GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 4.4.6. Canada GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 5.1. Europe GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 5.1.1. Integrated GLP-1/CGM Digital Platforms
    • 5.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 5.1.3. Others
  • 5.2. Europe GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 5.2.1. Individuals with Type 2 Diabetes
    • 5.2.2. Weight Management Patients (Non-Diabetic)
    • 5.2.3. Others
  • 5.3. Europe GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 5.3.1. Direct-to-Consumer/Telehealth
    • 5.3.2. Clinical/Provider-Prescribed
  • 5.4. Europe GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 5.4.1. Germany GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.2. Germany GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.3. Germany GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.4. Italy GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.5. Italy GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.6. Italy GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.7. France GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.8. France GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.9. France GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.10. U.K. GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.11. U.K. GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.12. U.K. GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.13. Spain GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.14. Spain GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.15. Spain GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.16. Russia GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.17. Russia GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.18. Russia GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.19. Rest of Europe GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.20. Rest of Europe GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.21. Rest of Europe GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 6.1.1. Integrated GLP-1/CGM Digital Platforms
    • 6.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 6.1.3. Others
  • 6.2. Asia Pacific GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 6.2.1. Individuals with Type 2 Diabetes
    • 6.2.2. Weight Management Patients (Non-Diabetic)
    • 6.2.3. Others
  • 6.3. Asia Pacific GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 6.3.1. Direct-to-Consumer/Telehealth
    • 6.3.2. Clinical/Provider-Prescribed
  • 6.4. Asia Pacific GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 6.4.1. China GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.2. China GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.3. China GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.4. Japan GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.5. Japan GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.6. Japan GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.7. South Korea GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.8. South Korea GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.9. South Korea GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.10. India GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.11. India GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.12. India GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.13. Southeast Asia GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.14. Southeast Asia GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.15. Southeast Asia GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.16. Rest of SAO GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.17. Rest of SAO GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.18. Rest of SAO GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 7.1. Latin America GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 7.1.1. Integrated GLP-1/CGM Digital Platforms
    • 7.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 7.1.3. Others
  • 7.2. Latin America GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 7.2.1. Individuals with Type 2 Diabetes
    • 7.2.2. Weight Management Patients (Non-Diabetic)
    • 7.2.3. Others
  • 7.3. Latin America GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 7.3.1. Direct-to-Consumer/Telehealth
    • 7.3.2. Clinical/Provider-Prescribed
  • 7.4. Latin America GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 7.4.1. Brazil GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 7.4.2. Brazil GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 7.4.3. Brazil GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.4. Mexico GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 7.4.5. Mexico GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 7.4.6. Mexico GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.7. Argentina GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 7.4.8. Argentina GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 7.4.9. Argentina GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.10. Rest of LATAM GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 7.4.11. Rest of LATAM GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 7.4.12. Rest of LATAM GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 8.1.1. Integrated GLP-1/CGM Digital Platforms
    • 8.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 8.1.3. Others
  • 8.2. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 8.2.1. Individuals with Type 2 Diabetes
    • 8.2.2. Weight Management Patients (Non-Diabetic)
    • 8.2.3. Others
  • 8.3. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 8.3.1. Direct-to-Consumer/Telehealth
    • 8.3.2. Clinical/Provider-Prescribed
  • 8.4. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 8.4.1. GCC GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.2. GCC GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.3. GCC GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.4. South Africa GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.5. South Africa GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.6. South Africa GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.7. Egypt GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.8. Egypt GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.9. Egypt GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.10. Nigeria GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.11. Nigeria GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.12. Nigeria GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.13. Rest of Middle East GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.14. Rest of Middle East GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.15. Rest of Middle East GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Dexcom, Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Abbott Laboratories
    • 9.4.3. Novo Nordisk A/S
    • 9.4.4. Eli Lilly and Company
    • 9.4.5. Medtronic plc
    • 9.4.6. Senseonics Holdings, Inc.
    • 9.4.7. Roche Holding AG
    • 9.4.8. Tandem Diabetes Care, Inc.
    • 9.4.9. Insulet Corporation
    • 9.4.10. Signos, Inc.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations